- Home
- NRC vs BNTC Comparison
NRC vs BNTC Comparison
Compare NRC & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRC | BNTC |
|---|---|---|
| Founded | 1981 | 1995 |
| Country | United States | United States |
| Employees | N/A | 24 |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.0M | 396.3M |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NRC | BNTC |
|---|---|---|
| Price | $21.87 | $11.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $27.67 |
| AVG Volume (30 Days) | 88.8K | ★ 100.1K |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | ★ 4707.69 | 6.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $119,686,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.81 | N/A |
| 52 Week Low | $11.01 | $9.85 |
| 52 Week High | $23.68 | $16.76 |
Technical Indicators
Market Signals| Indicator | NRC | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 53.34 | 36.36 |
| Support Level | $21.20 | $10.04 |
| Resistance Level | $21.74 | $14.14 |
| Average True Range (ATR) | 0.85 | 0.66 |
| MACD | -0.02 | -0.16 |
| Stochastic Oscillator | 73.31 | 14.61 |
Price Performance
Historical ComparisonAbout NRC National Research Corporation (Delaware)
NRC Health operates as a humanized healthcare and support organization. Its platform includes Listen, Understand, and Improve. The group provides solutions for Patient, Consumer, Employee, and Market experiences. The group's commitment to Human Understanding helps healthcare systems get to know the patients, families, consumers, employees, and communities it on a human level.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.